 |
Publications |
|
| (English refereed journals 2000-2001 only) |
| 1) |
Urinary excretion of type IV collagen
as a clinical indicator of the progression
of diabetic nephropathy; H.Watanabe, T.
Katoh, T. Watanabe et al. Nephron 86, 27-35
(2000) |
| 2) |
Inhibitory action of troglitazone, an
insulin-sensitizing agent, on the calcium
current in cardiac
Ventricular cells of guinea pig; Yoko Katoh,
Shigeatsu Hashimoto, Junko Kimura and T.Watanabe
Jpn. J.Pharmacol. 82, 102-109 (2000) |
| 3) |
Association of the nitric oxide synthesis
gene polymorphism with an increased risk
for progression to diabetic nephropathy
in type 2 diabetes; S.Neugebauer, T.Baba
and T.Watanabe. Diabetes 49, 500-503 (2000) |
| 4) |
Nitric oxide inhibits the formation of
advanced glycation endproducts.
K. Asahi, K. Ichimori, H. Nakazawa, Y. Izuhara,
T. Watanabe, K. Kurokawa, T. Miyata.Kidney
Int. 58, 1780-1787 (2000) |
| 5) |
Enhancement by homocysteine of plasminogen
activator inhibitor-1 gene expression and
secretion from vascular endothelial cells;
S. Midorikawa, H. Sanada, S. Hashimoto,
T. Watanabe Biochem.Biophys.Res.Commun.
272, 182-185 (2000) |
| 6) |
SSPG titer is a diagnostic marker for
adrenocortical adenoma in patients with
non-functioning adrenal incidentaloma. S.
Hashimoto, S. Midorikawa, H. Sanada, T.
Watanabe
Biomed.Pharmacother. 54, suppl. 1: 175-177
(2000) |
| 7) |
Improvement by an insulin-sensitizing
drug, troglitazone, of abnormal fibrinolysis
in type 2 diabetes mellitus; K. Katoh, D.
Yamada, S.Midorikawa, W.Satoh, T. Watanabe.
Metabolism 49: 662-665 (2000) |
| 8) |
Oral insulin sensitizer, thiazolidinedione,
increases plasma VEGF in type 2 diabetic
patients; T. Baba, K. Shimada, S.Neugebauer,
D.Yamada, S.Hashimoto & T.Watanabe
Diabetes Care 24: 953-954 (2001) |
| 9) |
The product of the duration and amount
of proteinuria (proteinuria index) is a
possible marker for glomerular and tubulointestinal
damage in IgA nephropathy. M.Eiro, T.Katoh
et al.
Nephron (in press, 2001) |
| 10) |
Analysis of cortisol secretion in hormonally
inactive adreno-cortical incidentalomas:
Study of in vitro steroid secretion and
immunohistochemical localization of steroidogenic
enzymes;
S. Midrikawa, H. Sanada, S.Hahsimoto, T.Suzuki,
T.Watanabe & H.Sasano
Endrine J. 48, 167-6 174 (2001) |
| 11) |
Seasonal variation of glycemic control
in type 2 diabetic patients; H.Ishi, H.Suzuki,
T.Baba,
K.Nakamura, T.Watanabe. Diabetes Care 24,
1503 (2001) |
| 12) |
The involvement of insulin resistance
in patients with adrenal incidentaloma by
surgical
resection; S. Midorikawa, H. Sanada, S.
Hashimoto, T. Suzuki, T. Watanabe
Clin. Endorinol. 54: 797-804 (2001) |
| 13) |
Hyporeninemic hypoaldosteronism associated
with Sjogren syndrome; A. Onozaki, T.Katoh,
T.Watanabe. Am. J. Med. (in press, 2001) |
| 14) |
Effect of proton-pump inhibitor on metabolic
alkalosis and hypoalemia in anorexia/bulimia
nervosa. M.Eiro, T.Katoh & T.Watanabe
N.Eng.J.Med. (in press) |
| 15) |
Recovery from renal failure in malignant
hypertension associated with primary aldosteronism:
Effect of ACE inhibitor; H.Suzuki, K.Asano,
M.Eiro, M.Kuriki, S.Hashimoto, K.Watanabe,T.Katoh,
& T.Watanabe. QJM (in press, 2001) |
|
|
